PUBLICATIONS
Explore our posters and presentations.
We are passionate about our mission to cure HBV, as well as our voice in the scientific community. That’s why we regularly publish meaningful content on our dynamic pipeline of therapeutics. Explore our scientific publications by format or asset.
IM-PROVE I: Imdusiran in Combination With Short Courses of Pegylated Interferon Alfa-2a in Virally Suppressed, HBeAg-Negative Subjects With Chronic HBV (CHB) Infection Leads to Functional Cure
IM-PROVE I: Imdusiran in Combination With Short Courses of Pegylated Interferon Alfa-2a in Virally Suppressed, HBeAg-Negative Subjects With Chronic HBV (CHB) Infection Leads to Functional CurePreliminary Antiviral Efficacy and Safety of Repeat Dosing of Imdusiran (AB-729) Followed by VTP-300 With or Without Nivolumab in Virally-Suppressed, Non-Cirrhotic Subjects With Chronic Hepatitis B (CHB)
Preliminary Antiviral Efficacy and Safety of Repeat Dosing of Imdusiran (AB-729) Followed by VTP-300 With or Without Nivolumab in Virally-Suppressed, Non-Cirrhotic Subjects With Chronic Hepatitis B (CHB)HBV Target Site for the RNA Interference Therapeutic Imdusiran is Highly Conserved in Chronic Hepatitis B Subjects
HBV Target Site for the RNA Interference Therapeutic Imdusiran is Highly Conserved in Chronic Hepatitis B SubjectsSoluble Immune Biomarker Profiling of Chronic Hepatitis B Subjects Treated with Imdusiran in Combination with Pegylated Interferon Alfa Reveals Phases of Immune Activation
Soluble Immune Biomarker Profiling of Chronic Hepatitis B Subjects Treated with Imdusiran in Combination with Pegylated Interferon Alfa Reveals Phases of Immune ActivationImdusiran Combinations Achieving HBsAg Loss
Imdusiran Combinations Achieving HBsAg LossImdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran alone
Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran aloneImdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment
Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatmentCuring Chronic Viral Hepatitis: A Story of Transformational Success and Another of Enduring Hope
Curing Chronic Viral Hepatitis: A Story of Transformational Success and Another of Enduring HopeManuscript: Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161
Manuscript: Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161Progress towards a functional cure for hepatitis B
Progress towards a functional cure for hepatitis BThe RNA Interference Therapeutic Imdusiran Retains Activity Against HBsAg in Chronic Hepatitis B Subjects with Baseline Nucleotide Polymorphisms Within the HBV Target Site
The RNA Interference Therapeutic Imdusiran Retains Activity Against HBsAg in Chronic Hepatitis B Subjects with Baseline Nucleotide Polymorphisms Within the HBV Target SiteBaseline nucleotide polymorphisms within HBV target site in chronic hepatitis B subjects do not impact HBsAg reductions mediated by RNA interference therapeutic Imdusiran (AB-729)
Baseline nucleotide polymorphisms within HBV target site in chronic hepatitis B subjects do not impact HBsAg reductions mediated by RNA interference therapeutic Imdusiran (AB-729)Oral Small-Molecule Liver-Tropic PD-L1 Inhibitor Pharmacokinetics for the Treatment of Hepatocellular Carcinoma
Oral Small-Molecule Liver-Tropic PD-L1 Inhibitor Pharmacokinetics for the Treatment of Hepatocellular CarcinomaPreliminary pharmacodynamics and safety of repeat dosing of imdusiran (AB-729) followed by VTP-300 or placebo in virally-suppressed, non-cirrhotic subjects with chronic hepatitis B (CHB)
Preliminary pharmacodynamics and safety of repeat dosing of imdusiran (AB-729) followed by VTP-300 or placebo in virally-suppressed, non-cirrhotic subjects with chronic hepatitis B (CHB)Imdusiran: Sustained HBsAg Suppression and Host Immune Control
Imdusiran: Sustained HBsAg Suppression and Host Immune ControlPreliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection
Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infectionHepatitis B virus core protein variant profiles observed in chronic hepatitis B patients treated with capsid inhibitor AB-836
Hepatitis B virus core protein variant profiles observed in chronic hepatitis B patients treated with capsid inhibitor AB-836Update on AB-729, an RNAi therapeutic in Phase 2 development as a key component of a functional cure strategy for cHBV
Update on AB-729, an RNAi therapeutic in Phase 2 development as a key component of a functional cure strategy for cHBVBiochemical characterization of AB-343, a novel, potent, and orally bioavailable SARS-CoV-2 main protease inhibitor with a pan-coronavirus profile
Biochemical characterization of AB-343, a novel, potent, and orally bioavailable SARS-CoV-2 main protease inhibitor with a pan-coronavirus profile48 weeks of AB-729 + nucleos(t)ide analogue (NA) therapy results in profound, sustained HBsAg declines in both HBeAg+ and HBeAg- subjects which are maintained in HBeAg- subjects who have discontinued all therapy
48 weeks of AB-729 + nucleos(t)ide analogue (NA) therapy results in profound, sustained HBsAg declines in both HBeAg+ and HBeAg- subjects which are maintained in HBeAg- subjects who have discontinued all therapyPreclinical Antiviral Profiling of AB-161, an Oral HBV Inhibitor that Destabilizes HBV RNA and Suppresses HBsAg
Preclinical Antiviral Profiling of AB-161, an Oral HBV Inhibitor that Destabilizes HBV RNA and Suppresses HBsAgIn Vitro Antiviral Profile of AB-343, a Novel, Oral, Potent SARS-CoV-2 Mpro Inhibitor with Pan-coronavirus Activity
In Vitro Antiviral Profile of AB-343, a Novel, Oral, Potent SARS-CoV-2 Mpro Inhibitor with Pan-coronavirus ActivityEvidence of T Cell Restoration after siRNA Therapy
Evidence of T Cell Restoration after siRNA TherapyHepatitis B viral control maintained during extended follow up of HBeAg- chronic hepatitis B (CHB) subjects who discontinued nucleos(t)ide analogue (NA) therapy after completion of AB-729 treatment, and in HBeAg+ subjects still on NA therapy
Hepatitis B viral control maintained during extended follow up of HBeAg- chronic hepatitis B (CHB) subjects who discontinued nucleos(t)ide analogue (NA) therapy after completion of AB-729 treatment, and in HBeAg+ subjects still on NA therapyCombination Treatment with HBV-Targeting GalNAc-siRNA and Small-Molecule PD-L1 Inhibitor Increases HBV Specific Immune Responses in a Chronic Hepatitis B Infection Mouse Model
Combination Treatment with HBV-Targeting GalNAc-siRNA and Small-Molecule PD-L1 Inhibitor Increases HBV Specific Immune Responses in a Chronic Hepatitis B Infection Mouse ModelEvaluation of the Vebicorvir, NRTI and AB-729 Combination in virologically Suppressed Patients with HBeAg Negative Chronic Hepatitis B Virus Infection: Interim Analysis from an Open Label Phase 2 Study
Evaluation of the Vebicorvir, NRTI and AB-729 Combination in virologically Suppressed Patients with HBeAg Negative Chronic Hepatitis B Virus Infection: Interim Analysis from an Open Label Phase 2 StudyCombination treatment with AB-101, a small-molecule PD-L1 Inhibitor, and an HBV-targeting GalNAc-siRNA increases HBV-specific immune responses in a chronic Hepatitis B infection mouse model
Combination treatment with AB-101, a small-molecule PD-L1 Inhibitor, and an HBV-targeting GalNAc-siRNA increases HBV-specific immune responses in a chronic Hepatitis B infection mouse modelAB-161, an Oral HBV RNA Destabilizer to Suppress HBV RNA and HBsAg
AB-161, an Oral HBV RNA Destabilizer to Suppress HBV RNA and HBsAgCombination treatment with AB-101, a small-molecule PD-L1 Inhibitor, and an HBV-targeting GalNAc-siRNA increases HBV-specific immune responses in a chronic Hepatitis B infection mouse model
Combination treatment with AB-101, a small-molecule PD-L1 Inhibitor, and an HBV-targeting GalNAc-siRNA increases HBV-specific immune responses in a chronic Hepatitis B infection mouse modelContinued suppression of viral markers observed following discontinuation of nucleos(t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729
Continued suppression of viral markers observed following discontinuation of nucleos(t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729Long-term HBsAg suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects
Long-term HBsAg suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjectsPharmacodynamics of durable HBsAg suppression by AB-729 short interfering RNA correlates with pharmacokinetics of RNA-induced silencing complex (RISC) loading within liver
Pharmacodynamics of durable HBsAg suppression by AB-729 short interfering RNA correlates with pharmacokinetics of RNA-induced silencing complex (RISC) loading within liverInhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA+ chronic hepatitis B subjects
Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA+ chronic hepatitis B subjectsReduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells
Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cellsPreclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patients
Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patientsInhibition of PAPD5 and PAPD7 by Small-Molecule HBV RNA Destabilizers from DHQ and THP Chemical Series
International Conference on Antiviral Research (ICAR)
Inhibition of PAPD5 and PAPD7 by Small-Molecule HBV RNA Destabilizers from DHQ and THP Chemical SeriesProgress Toward an HBV Cure Combination Therapy
Hep DART 2021
Progress Toward an HBV Cure Combination TherapyLow HBsAg levels maintained following cessation of the GalNAc-siRNA, AB-729, in chronic hepatitis B subjects on nucleos(t)ide analogue therapy
Low HBsAg levels maintained following cessation of the GalNAc-siRNA, AB-729, in chronic hepatitis B subjects on nucleos(t)ide analogue therapyClinical Overview of AB-729, a potent siRNA in development for the treatment of chronic hepatitis B infection
The Science of HBV Cure Meeting 2021 (Virtual)
Clinical Overview of AB-729, a potent siRNA in development for the treatment of chronic hepatitis B infectionKinetics of HBV DNA replication, cccDNA formation and HBsAg production in a “pgRNA launch” HBV replication system and its susceptibility to antiviral agents
2021 International HBV Meeting
Kinetics of HBV DNA replication, cccDNA formation and HBsAg production in a “pgRNA launch” HBV replication system and its susceptibility to antiviral agentsClinical Update Based on Data Presented at the EASL International Liver Congress™ 2021
EASL International Liver Congress™ 2021
Clinical Update Based on Data Presented at the EASL International Liver Congress™ 2021Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T-cell activation markers
EASL International Liver Congress™ 2021
Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T-cell activation markersInhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms and HBV RNA
EASL International Liver Congress™ 2021
Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms and HBV RNAA single dose of the GalNAc-siRNA AB-729 results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos(t)ide analogue therapy in HBeAg- subjects with chronic hepatitis B infection
EASL International Liver Congress™ 2021
A single dose of the GalNAc-siRNA AB-729 results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos(t)ide analogue therapy in HBeAg- subjects with chronic hepatitis B infectionRepeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression
EASL International Liver Congress™ 2021
Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppressionAn RNAi for the Treatment of Chronic Hepatitis B Infection: Clinical Update
Chronic Hepatitis B Drug Development Summit
An RNAi for the Treatment of Chronic Hepatitis B Infection: Clinical UpdateAB‐729, a GalNAc‐siRNA, results in robust reductions of HBV DNA and HBsAg in subjects with chronic hepatitis B infection APASL 2021
AB‐729, a GalNAc‐siRNA, results in robust reductions of HBV DNA and HBsAg in subjects with chronic hepatitis B infection APASL 2021Safety and pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B infection
The Liver Meeting Digital Experience™ | AASLD
Safety and pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B infection
Coronavirus
Learn more about how we are innovating in pan-coronavirus treatment.